Article
Identification of a predictive biomarker for hematologic toxicities of gemcitabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 May 2009
Matsubara Junichi, Ono Masaya, Negishi Ayako, Ueno Hideki, Okusaka Takuji, Furuse Junji, Furuta Koh, Sugiyama Emiko, Saito Yoshiro, Kaniwa Nahoko, Sawada Junichi, Honda Kazufumi, Sakuma Tomohiro, Chiba Tsutomu, Saijo Nagahiro, Hirohashi Setsuo, Yamada Tesshi
Abstract excerpt
PURPOSE: Gemcitabine monotherapy is the current standard for patients with advanced pancreatic cancer, but the occurrence of severe neutropenia and thrombocytopenia can sometimes be life threatening. This study aimed to discover a new diagnostic method for predicting the hematologic toxicities of gemcitabine. PATIENTS AND METHODS: Using quantitative mass spectrometry (MS), we compared the baseline plasma...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.